Chinese biopharma Mabwell raises $278m in Series A round led by Shiyu Capital

Source: Laurynas Mereckas/Unsplash

Chinese innovative biopharmaceutical firm Mabwell BioScience has closed 1.97 billion yuan ($278 million) in a Series A round of financing led by the country’s private equity firm Shenzhen Shiyu Investment Management.

A group of Chinese domestic companies participated in the round, including venture capital company Oriental Fortune Capital, Hong Kong-listed Haitong Securities’ private equity unit Haitong Capital, and Loyal Valley Capital (LVC), a private equity firm that invests in middle-market companies, said Mabwell in a WeChat post on Tuesday.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter